Marvel Biosciences Corp.
MRVL.V
TSX
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.42% | 2.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 101.99% | -52.62% | |||
| Operating Income | -101.99% | 52.62% | |||
| Income Before Tax | -378.35% | 47.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -378.35% | 47.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -378.35% | 47.00% | |||
| EBIT | -101.99% | 52.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -320.51% | 48.68% | |||
| Normalized Basic EPS | -325.00% | 50.00% | |||
| EPS Diluted | -320.51% | 48.68% | |||
| Normalized Diluted EPS | -325.00% | 50.00% | |||
| Average Basic Shares Outstanding | 13.34% | 4.33% | |||
| Average Diluted Shares Outstanding | 13.34% | 4.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||